(Q35145704)

6 August 2017

1 reference

title

Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment (English)

1 reference

6 August 2017

1 reference

1 reference

Colby L Eaton

1

1 reference

6 August 2017

R E Coleman

series ordinal

2

1 reference

6 August 2017

language of work or name

1 reference

1 June 2003

1 reference

6 August 2017

published in

Cancer Treatment Reviews

1 reference

6 August 2017

volume

29

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

189-198

1 reference

6 August 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Quantitative histology of myeloma-induced bone changes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Bone-Resorbing Activity in Supernatants from Lymphoid Cell Lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Evidence for the secretion of an osteoclast stimulating factor in myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Human myeloma cells promote the recruitment of osteoblast precursors: mediation by interleukin-6 and soluble interleukin-6 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Clinical significance of elevated soluble interleukin‐6 receptor levels in the sera of patients with plasma cell dyscrasias

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

TGF-beta signalling from cell membrane to nucleus through SMAD proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Identification of a messenger ribonucleic acid fraction in human prostatic cancer cells coding for a novel osteoblast-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

The role of glucocorticoids and prostaglandin E2 in the recruitment of bone marrow mesenchymal cells to the osteoblastic lineage: positive and negative effects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Ca(2+)-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Interleukin-6: a candidate mediator of human prostate cancer morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen-independent growth in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Bone cancer gain without the pain

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Human bone marrow myeloma cells express RANKL

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Steering anti-cancer drugs away from the TRAIL

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Generalised increase in bone resorption in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Morphometric evidence for bone resorption and replacement in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Ibandronate in the treatment of prostate cancer associated painful osseous metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900071-9

7 January 2021

10.1016/S0305-7372(03)00071-9

Identifiers

DOI

1 reference

6 August 2017

1 reference